Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

References

• Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50:S412–16.
   PubMed Web of Science ®Google Scholar
• Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171–80.
   PubMed Web of Science ®Google Scholar
• Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009;8:S18–24.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539–64.
   PubMed Web of Science ®Google Scholar
• Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008;2:705–11.
   PubMedGoogle Scholar
• Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009;42:802–7.
   PubMedGoogle Scholar
• Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010;314:1–16.
   PubMed Web of Science ®Google Scholar
• Kobayashi K. Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 2005;6:525–9.
   PubMed Web of Science ®Google Scholar
• Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957–69.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299–314.
   PubMedGoogle Scholar
• Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412–21.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670.
   PubMed Web of Science ®Google Scholar
• Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253–61.
   PubMed Web of Science ®Google Scholar
• Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29–33.
   PubMed Web of Science ®Google Scholar
• de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655–61.
   PubMed Web of Science ®Google Scholar
• Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007;362:1013–18.
   PubMed Web of Science ®Google Scholar
• Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010;45:235–42.
   PubMed Web of Science ®Google Scholar
• Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010;95:2892–6.
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Cianflone K. The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. World Rev Nutr Diet 1997;80:44–81.
   PubMedGoogle Scholar
• Gabrielsson BG, Johansson JM, Lönn M, Jernås M, Olbers T, Peltonen M, High expression of complement components in omental adipose tissue in obese men. Obes Res 2003;11:699–708.
   PubMedGoogle Scholar
• Fain JN, Nesbit AS, Sudlow FF, Cheema P, Peeples JM, Madan AK, Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes. Metabolism 2007;56:1583–90.
   PubMedGoogle Scholar
• ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29:1955–62.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
   PubMed Web of Science ®Google Scholar
• Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802–7.
   PubMed Web of Science ®Google Scholar
• Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Hepatocellular ballooning in NASH. J Hepatol 2010; doi:10.1016/j.jhep.2010.04.031.
   Google Scholar
• Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086–7.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Dolar E. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decorations? World J Gastroenterol 2009;15:4346–7.
   PubMedGoogle Scholar
• Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009;15:4387–91.
   PubMed Web of Science ®Google Scholar
• Kos K, Wilding JP. Adipokines: emerging therapeutic targets. Curr Opin Investig Drugs 2009;10:1061–8.
   PubMedGoogle Scholar